ArticleObesity surgery2022
Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis.
Article in Obesity surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trial
- Endobariatric Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.Biomedicines · 2026Review
- UDFF and Auto pSWE accurately assess liver steatosis and fibrosis risk in obese patients with MASLD.Ultraschall in der Medizin (Stuttgart, Germany : 1980) · 2025Article
- Advances and future directions in endoscopic bariatric therapies.World journal of gastrointestinal endoscopy · 2025Review
- Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications.Biomedicines · 2025Review
- Impact of metabolic endoscopy on fibrosis regression in steatotic liver disease.World journal of hepatology · 2025Review
- Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review.Journal of clinical medicine · 2025Review
- Satiety Hormone LEAP2 After Low-Calorie Diet With/Without Endobarrier Insertion in Obesity and Type 2 Diabetes Mellitus.Journal of the Endocrine Society · 2024Article
- Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control.Clinical endoscopy · 2024Review
- Removable Transduodenal Bypass: Development of a New Endoscopic Concept.Visceral medicine · 2023Article
- A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going.Medicina (Kaunas, Lithuania) · 2023Review
- Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis.Clinical and molecular hepatology · 2023Review
- Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area.Diagnostics (Basel, Switzerland) · 2022Review
- Endo-bariatric therapies as a treatment strategy for MASLD.Clinical liver diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePeople with obesity often develop non-alcoholic fatty liver disease (NAFLD) and are at high risk of progression to non-alcoholic steatohepatitis (NASH). Few therapies are effective other than bariatric surgery. We therefore analyzed data from duodenal-jejunal bypass liner (DJBL) patients regarding steatosis, fibrosis, and NASH.
methodsConsecutive DJBL patients with type 2 diabetes underwent standardized assessments up to device removal at 48 weeks. These included aspartate and alanine transaminase (AST, ALT), controlled attenuation parameter (CAP, for steatosis), and liver stiffness measurement (LSM, for fibrosis). The NAFLD fibrosis score (NFS), fibrosis-4 score (FIB4), and enhanced liver fibrosis (ELF) test were also used to assess fibrosis and the Fibroscan-AST (FAST) score to assess NASH. Mixed models were used and missing data were accounted for with multiple imputation.
resultsThirty-two patients (18 female, mean age 55.1, mean BMI 40.2 kg/m
conclusionsOne year of DJBL therapy is associated with relevant improvements in non-invasive markers of steatosis and NASH, but not fibrosis, and is accompanied by a substantial number of complications. Given the lack of alternatives, DJBL deserves further attention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.